May 29, 2026 07:00 AM EDT
Peer Review
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Alex Hoffman
Copy Chief and News Editor
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by the company’s current chief medical officer Zachary Roberts.
May 29, 2026 07:00 AM EDT
Peer Review
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Alex Hoffman
Copy Chief and News Editor

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease…

Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The…

Peter Griffith will be the second high-profile exec to leave Amgen this year when he retires on Sept. 1. Thomas Dittrich will…

Biohaven Announces Scientific Leadership Transitions

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year. …

Before Katherine Stueland took the top job at genetic testing company GeneDx she had never thought of herself as the CEO type,…